Compare Stocks

Date Range: 

 Madrigal PharmaceuticalsMacroGenicsSeres TherapeuticsKura OncologyCytoDyn
SymbolNASDAQ:MDGLNASDAQ:MGNXNASDAQ:MCRBNASDAQ:KURAOTCMKTS:CYDY
Price Information
Current Price$132.05$30.48$22.60$25.39$2.80
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.71.41.71.61.1
Analysis Score3.42.43.43.53.0
Community Score2.82.53.02.72.6
Dividend Score0.00.00.00.00.0
Ownership Score2.51.71.71.70.0
Earnings & Valuation Score0.00.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$167.60$34.30$39.00$39.45$4.00
% Upside from Price Target26.92% upside12.53% upside72.57% upside55.39% upside42.86% upside
Trade Information
Market Cap$2.17 billion$1.83 billion$1.84 billion$1.64 billion$1.73 billion
Beta1.192.44.072.15-0.64
Average Volume165,603773,997974,209712,1734,236,808
Sales & Book Value
Annual RevenueN/A$64.19 million$34.51 millionN/AN/A
Price / SalesN/A28.5160.00N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$27.00 per share$4.71 per share($0.69) per share$4.83 per share($0.01) per share
Price / BookN/A6.47-32.75N/AN/A
Profitability
Net Income$-83,950,000.00$-151,810,000.00$-70,280,000.00$-63,140,000.00$-124,400,000.00
EPS($5.45)($3.16)($1.20)($1.51)($0.21)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-204.31%-385.22%N/AN/A
Return on Equity (ROE)-47.64%-65.84%-2,867.98%-30.96%N/A
Return on Assets (ROA)-43.21%-49.41%-51.24%-28.02%-153.30%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.13%0.02%5.01%
Current Ratio6.84%6.19%6.73%15.15%1.13%
Quick Ratio6.84%6.19%6.73%15.15%0.28%
Ownership Information
Institutional Ownership Percentage74.24%95.80%94.32%94.72%0.10%
Insider Ownership Percentage41.89%9.00%4.80%11.00%7.80%
Miscellaneous
Employees423701558819
Shares Outstanding16.49 million60.04 million91.62 million66.27 million619.04 million
Next Earnings Date8/5/2021 (Estimated)7/29/2021 (Estimated)7/27/2021 (Estimated)8/5/2021 (Estimated)8/13/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY - Yahoo FinanceROSEN, TRUSTED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY - Yahoo Finance
finance.yahoo.com - May 10 at 7:50 PM
CYDY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: May 17, 2021 - Yahoo FinanceCYDY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: May 17, 2021 - Yahoo Finance
finance.yahoo.com - May 10 at 7:50 PM
CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo FinanceCYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo Finance
finance.yahoo.com - May 10 at 2:49 PM
CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action LawsuitCYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit
feeds.benzinga.com - May 9 at 4:05 PM
CytoDyn (CYDY) Stock Consolidates In Absence Of Any Catalyst – Own Snap - Own SnapCytoDyn (CYDY) Stock Consolidates In Absence Of Any Catalyst – Own Snap - Own Snap
ownsnap.com - May 9 at 1:28 PM
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Clearfield ProgressDeadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Clearfield Progress
theprogressnews.com - May 9 at 12:34 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY - Marketscreener.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY - Marketscreener.com
marketscreener.com - May 8 at 7:30 PM
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc.Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc.
prnewswire.com - May 8 at 3:06 PM
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Bradford EraDeadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Bradford Era
bradfordera.com - May 8 at 2:17 PM
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc.Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc.
finance.yahoo.com - May 8 at 2:17 PM
CytoDyn (OTCMKTS:CYDY) Shares Up 8.2%CytoDyn (OTCMKTS:CYDY) Shares Up 8.2%
americanbankingnews.com - May 8 at 12:16 AM
CytoDyn strikes agreement with AEIH in Brazil to run two coronavirus trials using its flagship drug leronlimab - Proactive Investors USA & CanadaCytoDyn strikes agreement with AEIH in Brazil to run two coronavirus trials using its flagship drug leronlimab - Proactive Investors USA & Canada
proactiveinvestors.com - May 7 at 8:00 PM
CytoDyn, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - StockhouseCytoDyn, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Stockhouse
stockhouse.com - May 7 at 3:00 PM
SHAREHOLDER ALERT: CYDY KRMD CCXI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesSHAREHOLDER ALERT: CYDY KRMD CCXI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
finance.yahoo.com - May 7 at 3:00 PM
CytoDyns Leronlimab Featured on OneNews in Philippines on May 9 - GlobeNewswireCytoDyn's Leronlimab Featured on OneNews in Philippines on May 9 - GlobeNewswire
globenewswire.com - May 7 at 9:59 AM
CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9
finance.yahoo.com - May 7 at 9:59 AM
CytoDyn and AEIH to begin trials of leronlimab in severe Covid-19 - Clinical Trials ArenaCytoDyn and AEIH to begin trials of leronlimab in severe Covid-19 - Clinical Trials Arena
clinicaltrialsarena.com - May 6 at 6:21 PM
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. - Yahoo FinanceClass Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. - Yahoo Finance
finance.yahoo.com - May 6 at 1:20 PM
CytoDyn: Suitable For Trading Not Investing - Seeking AlphaCytoDyn: Suitable For Trading Not Investing - Seeking Alpha
seekingalpha.com - May 6 at 1:20 PM
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CYDY, NEPT and ACADThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of CYDY, NEPT and ACAD
finance.yahoo.com - May 6 at 1:20 PM
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action - CYDY - Yahoo FinanceROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action - CYDY - Yahoo Finance
finance.yahoo.com - May 5 at 11:52 PM
Lawsuits Filed Against CYDY, DOX and PTON - Jakubowitz Law Pursues Shareholders ClaimsLawsuits Filed Against CYDY, DOX and PTON - Jakubowitz Law Pursues Shareholders Claims
finance.yahoo.com - May 5 at 6:48 PM
CYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo FinanceCYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo Finance
finance.yahoo.com - May 5 at 1:48 PM
CYDY DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against CytoDyn, Inc. – CYDY - Yahoo FinanceCYDY DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against CytoDyn, Inc. – CYDY - Yahoo Finance
finance.yahoo.com - May 5 at 1:48 PM
CYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action LawsuitCYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit
finance.yahoo.com - May 5 at 1:48 PM
DateCompanyBrokerageAction
3/4/2021Madrigal PharmaceuticalsChardan CapitalBoost Price Target
3/2/2021Madrigal PharmaceuticalsOppenheimerLower Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/12/2020Madrigal PharmaceuticalsCanaccord GenuityLower Price Target
11/6/2020Madrigal PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
11/6/2020Madrigal PharmaceuticalsBMO Capital MarketsBoost Price Target
11/6/2020Madrigal PharmaceuticalsHC WainwrightBoost Price Target
11/5/2020Madrigal PharmaceuticalsPiper SandlerLower Price Target
8/6/2020Madrigal PharmaceuticalsStifel NicolausReiterated Rating
5/22/2020Madrigal PharmaceuticalsB. RileyBoost Price Target
3/5/2020Madrigal PharmaceuticalsCitigroupLower Price Target
5/6/2021MacroGenicsSVB LeerinkBoost Price Target
5/3/2021MacroGenicsMorgan StanleyBoost Price Target
3/18/2021MacroGenicsBarclaysUpgrade
6/1/2020MacroGenicsGuggenheimUpgrade
12/23/2020Seres TherapeuticsJMP SecuritiesInitiated Coverage
8/11/2020Seres TherapeuticsJefferies Financial GroupUpgrade
5/5/2021Kura OncologyCredit Suisse GroupInitiated Coverage
12/7/2020Kura OncologyWedbushBoost Price Target
10/8/2020Kura OncologyCSFBBoost Price Target
8/16/2020Kura OncologyBrookline Capital ManagementReiterated Rating
5/19/2020Kura OncologyDeutsche Bank AktiengesellschaftLower Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.